# Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Article · Steven P. Marso, Gilbert H. Daniels, Kirstine Brown‐Frandsen, Peter Lommer Kristensen, Johannes F.E. Mann, Michael Albrecht Nauck, Steven E. Nissen, Stuart Pocock, Neil R Poulter, Lasse Steen Ravn, William M. Steinberg, Mette Stockner, Bernard Zinman, Richard M. Bergenstal, John B. Buse

- Archive id: doi:10.1056/nejmoa1603827
- Published: 2016-06-13
- Venue: New England Journal of Medicine
- DOI: https://doi.org/10.1056/nejmoa1603827
- PMID: 27295427
- PMCID: PMC4985288
- Citations: 7,620
- Source URL: https://doi.org/10.1056/nejmoa1603827
- PDF: https://www.nejm.org/doi/pdf/10.1056/NEJMoa1603827?articleTools=true
- Provenance: openalex

_Abstract not reproduced: its license does not permit redistribution. See the source URL._

Topics: [GLP-1 & Incretin Therapies](https://space-kitty.com/topics/glp1-metabolic)

Cited in dossiers:
- [GLP-1 & Incretin Therapies: State of the Field (October 2026)](https://space-kitty.com/dossiers/glp1-metabolic)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.